Oncology

Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases

Retrieved on: 
Friday, December 9, 2022
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology

Arterial Occlusive Events (AOEs): AOEs, including fatalities, have occurred in patients who received ICLUSIG in OPTIC and PACE.

Key Points: 
  • Arterial Occlusive Events (AOEs): AOEs, including fatalities, have occurred in patients who received ICLUSIG in OPTIC and PACE.
  • The incidence of AOEs in OPTIC (45 mg->15 mg) was 14% of 94 patients; 6% experienced Grade 3 or 4.
  • In OPTIC, patients with uncontrolled hypertension or diabetes and patients with clinically significant, uncontrolled, or active cardiovascular disease were excluded.
  • The incidence was higher in patients with Ph+ ALL (9% of 32 patients) and BP-CML (10% of 62 patients).

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Retrieved on: 
Friday, December 9, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Aenco, Therapy, Regulation D, Note, Menopause, JT Group Limited, Regulation D (SEC), Regulation, Research, Infection, Sale, Degenerative disease, Conversion, Liquid biopsy, Neuroblastoma, Prospectus, Agency for Science, Technology and Research, Autoimmunity, Euronext Paris, USD, MRSA, Pharmaceutical industry, Science, EU

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced a private offering of USD$3 million aggregate principal amount of convertible note due 2023 (the Note) to be used as part of the Companys daily operations and clinical program.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced a private offering of USD$3 million aggregate principal amount of convertible note due 2023 (the Note) to be used as part of the Companys daily operations and clinical program.
  • The Note will be solely subscribed by Aenco Technologies Limited (Investor) which is indirectly 34.56% effectively owned by Mr. Ian Huen, a Non-Executive Director and major shareholder of Aptorum Group.
  • The Note is unsecured, convertible into the Companys restricted Class A Ordinary Shares, par value $1.00 per share (the Ordinary Shares) at the Investor option.
  • This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

Bristol Myers Squibb Announces Dividend Increase

Retrieved on: 
Saturday, December 17, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NYSE, BMY, Bristol Myers Squibb, Patient, Holding company, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company.
  • This quarterly dividend represents a 5.6% increase over last years quarterly dividend rate of fifty-four cents ($0.54) per share.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ClinicalTrials.gov, Hemoptysis, Proteinuria, Fatal, Recurrence, Hepatocellular carcinoma, Bleeding, Melena, Immunotherapy, PD-L1, Union, Docetaxel, Avascular necrosis, Hypertension, Takeda Pharmaceutical Company, Hematemesis, Fistula, AST, Patient, Pulmonary embolism, ULN, Grade 3, Nivolumab, ONJ, NSCLC, Lung cancer, Venous thrombosis, Sepsis, Post-vaccination embolic and thrombotic events, Roche, Progression-free survival, HIV disease progression rates, Embolism, Nephrotic syndrome, Incidence, ALT, EXEL, VEGFR, Tablet, Survival, History, Sorafenib, DTC, Abscess, HCC, Adrenal insufficiency, Hormone replacement therapy, Perforation, RCC, Ipsen, Risk, Medical imaging, Pharmaceutical industry, Exelixis, Jaw, Takeda

Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

Key Points: 
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX in combination with atezolizumab is not indicated as a treatment for NSCLC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
  • Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients.
  • Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.

Interventional Oncology Global Market Report 2022: Demand for Minimally Invasive Treatments Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Health, Oncology, Breast, Liver, Patient, Prevalence, Oncology, Cancer, Government, Lung, Radiology, Hospital, Growth, Medical imaging

The "Interventional Oncology Market By Product: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interventional Oncology Market By Product: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global interventional oncology market size is expected to reach up to $3,791.50 million by 2030, surging from $2,131.30 million in 2021, at a noteworthy CAGR of 6.5%.
  • Interventional oncology therapies are very beneficial for the patients as these therapies are minimally invasive, have lesser time for the recovery, have very few side effects as compared to other treatments, and involves lesser discomfort.
  • Nowadays, interventional oncology is considered as an important component in the field of modern oncology care, cancer treatment, supporting numerous surgical, medical, and radiation oncology therapies.

Immunohistochemistry Global Market Report 2022: Rising Research and Development Activities for the Development of Innovative Products Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Research, Radiology, Pharmaceutical, Oncology, Medical Devices, Science, Chemicals, Plastics, Biotechnology, Neurology, Medical Supplies, Health, Other Science, Manufacturing, Antigen, PerkinElmer, Conditional sentence, Headache, Encephalitis, Diagnosis, Antibody, Neurological disorder, Disability-adjusted life year, Abcam, Hematology, Thermo Fisher Scientific, Prevalence, Cerebral palsy, Immunohistochemistry, IHC, US, Classification, Research, Epilepsy, Agilent Technologies, Reed Elsevier, Inc. v. Muchnick, Microbiology, Histology, Bio-Techne, Becton, Dickinson and Company headquarters, Growth, Miltenyi Biotec, Stroke, Application, Merck, Marketing, Serology, Neoplasm, Renewable energy, Fine chemical

The "Immunohistochemistry Market, by Product, by Application, by End User by Region, - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immunohistochemistry Market, by Product, by Application, by End User by Region, - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Antibodies are used in immunohistochemistry (IHC) to locate proteins and other antigens in tissue sections.
  • Either chromogenic detection using a colored enzyme substrate or fluorescence detection with a fluorescent dye is used to observe antibody-antigen interaction.
  • The increasing prevalence of chronic diseases, rising research and development activities for the development of innovative products, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in market are the major factors that are expected to drive growth of the global immunohistochemistry market over the forecast period.

Fashion meets philanthropy as celebrities and artists don This Shirt Saves Lives tee to support St. Jude Children’s Research Hospital

Retrieved on: 
Thursday, December 8, 2022
Health, Entertainment, Family, Consumer, Celebrity, Other Philanthropy, Philanthropy, Oncology, Parenting, Children, General Health, Hospitals, Fund Raising, Foundation, Travel, Social media, Housing, Food, National Cancer Institute, Sensation, Cancer, NCI-designated Cancer Center, The Bobby Bones Show, National Cancer Research Institute, Survival rate, Child, Personality, Love, Multimedia, Hospital, St. Jude Children's Research Hospital, Partner, Music, Nightclub, Hope, Jude the Apostle

This annual series of nationwide radiothons is part of the Music Gives to St. Jude Kids campaign that connects music lovers to the mission of St. Jude.

Key Points: 
  • This annual series of nationwide radiothons is part of the Music Gives to St. Jude Kids campaign that connects music lovers to the mission of St. Jude.
  • To upgrade your fashion game and help kids everywhere, join the This Shirt Saves Lives movement at thisshirtsaveslives.org .
  • St. Jude Childrens Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy

Retrieved on: 
Thursday, December 8, 2022
FDA, Technology, Nanotechnology, Stem Cells, Finance, Pharmaceutical, Managed Care, Oncology, Professional Services, Hospitals, Clinical Trials, Cardiology, Biotechnology, Science, Research, Health, ClinicalTrials.gov, III, Heart, TKI, Hepatocellular carcinoma, Exelixis, PD-L1, Union, Docetaxel, Risk, TAM, Takeda Pharmaceutical Company, Patient, Cancer, NSCLC, IPN, Progression-free survival, Roche, Business, HIV disease progression rates, ADR, Medicine, VEGFR, Cabozantinib, Survival, Sorafenib, Growth, Clinical trial, HCC, Combination therapy, Patent, Medical imaging, Pharmaceutical industry, Euronext, Research, Takeda, Neuroscience, Ipsen

CONTACT-01 is a phase III clinical trial evaluating Cabometyx (cabozantinib) in combination with atezolizumab (Tecentriq) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy.

Key Points: 
  • CONTACT-01 is a phase III clinical trial evaluating Cabometyx (cabozantinib) in combination with atezolizumab (Tecentriq) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy.
  • We wish to thank the patients, their families and healthcare teams for their participation in this clinical trial.
  • The study enrolled patients with both squamous and non-squamous NSCLC who progressed during or following anti-PD-1/PD-L1 therapy administered either concurrently or sequentially with chemotherapy.
  • Results from cohort 7 of the phase 1b COSMIC-021 trial informed the CONTACT-01 trial design.

Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, Genetics, Research, Pharmaceutical, Science, Security (finance), III, Analysis, ESR1, Financial condition report, Patient, Annual report, Breast cancer, AstraZeneca, GH, Aromatase, Health, Liquid biopsy, Result, Helmy Eltoukhy, Pharmaceutical industry

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it has entered into a collaboration with AstraZeneca to pursue the development, regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic to identify patients with ESR1-mutated metastatic breast cancer.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it has entered into a collaboration with AstraZeneca to pursue the development, regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic to identify patients with ESR1-mutated metastatic breast cancer.
  • Were pleased to collaborate with AstraZeneca on this important study for breast cancer patients, said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.
  • The Guardant Health screening portfolio, including the ShieldTM test, aims to address the needs of individuals eligible for cancer screening.

Cancer Immunotherapy Global Market Report 2022: Technological Advancements and Introduction of Novel Drugs Bolster Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Pharmaceutical, Health, Oncology, Genentech, Lymphoma, Immunotherapy, Johnson & Johnson, Cancer, Toxicity, NSCLC, Janssen Pharmaceuticals, AstraZeneca, Neutralizing antibody, Market share, FDA, Tumor microenvironment, Growth, Clinical trial, Breast, Radiation, Application, Brain, Astellas Pharma, USD, Pharmaceutical industry

The global cancer immunotherapy market is expected to reach USD 196.45 billion by 2030, registering CAGR of 7.2% during the forecast period.

Key Points: 
  • The global cancer immunotherapy market is expected to reach USD 196.45 billion by 2030, registering CAGR of 7.2% during the forecast period.
  • Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth.
  • Moreover, the robust product pipeline of the immunotherapy medicines for oncology is one of the major driving factors for strong growth of the market.
  • Furthermore, development and approval of the novel immunotherapy treatments for relapsed and refractory malignancies are accelerating the cancer immunotherapy market expansion.